p. 596−613
2357-061X
Vol.40/No.4
p. 614−636
2357-061X
Vol.40/No.4
p. 637−655
2357-061X
Vol.40/No.4
p. 656−676
2357-061X
Vol.40/No.4
p. 677−690
2357-061X
Vol.40/No.4
p. 691−704
2357-061X
Vol.40/No.4
p. 705−723
2357-061X
Vol.40/No.4
p. 724−738
2357-061X
Vol.40/No.4
p. 739−750
2357-061X
Vol.40/No.4
70-90 seconds) and strong intensity were found to be significantly higher in the misoprostol group compared to the oxytocin group (p<0.01). Within the first 12 hours, the misoprostol group recorded statistically significant higher rates of normal fetal heart rate and of vaginal delivery compared to the oxytocin group (p=0.003, 0.008 respectively). On the other hand, the incidence of cesarean delivery was higher in the oxytocin group compared to the misoprostol group. Conclusion and Recommendations: Misoprostol 25μg vaginally (every 4 hours, up to 200 μg) is more safe and efficient for cervical ripening than oxytocin infusion. It is recommended for parturient women with Bishop score ≤4.]]>
p. 751−767
2357-061X
Vol.40/No.4